Сatalase antibodies in patients with systemic scleroderma as a diagnostic and prognostic marker of the disease
The study covered 30 apparently healthy individuals and 38 patients with systemic scleroderma. The patients gave their consent to participate in the study in accordance with the World Medical Association Declaration of Helsinki in the current (2013) version (ACR/EULAR). The donors and patients had t...
Guardado en:
Autores principales: | O. I. Emelyanova, I. P. Gontar, O. A. Rusanova, I. A. Zborovskaya |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
SPb RAACI
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f1881343747c4f9ba22e7ea149c9d291 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
DIAGNOSTIC VALUE OF CERULOPLASMIN IN SYSTEMIC SCLERODERMA
por: O. I. Emelyanova, et al.
Publicado: (2019) -
Taxane-induced scleroderma. Report of two cases
por: Cury-Martins,Jade, et al.
Publicado: (2021) -
Clinical and Histopathological Features of Scleroderma-like Disorders: An Update
por: Rosario Foti, et al.
Publicado: (2021) -
Investigation of the Expression of Inflammatory Markers in Oral Biofilm Samples in Patients with Systemic Scleroderma and the Association with Clinical Periodontal Parameters—A Preliminary Study
por: Mayte Buchbender, et al.
Publicado: (2021) -
Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
por: Francesca Rosamilia, et al.
Publicado: (2021)